REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO (Nasdaq: RGNX) announced that it intends to conduct an underwritten public offering of $100 million of its common stock, subject to market and other conditions.

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) announced that it intends to conduct an underwritten public offering of $100 million of its common stock, subject to market and other conditions. The company noted there is no assurance regarding completion, timing, actual size or final terms of the offering.

According to REGENXBIO, the company also plans to grant underwriters a 30-day option to purchase up to 15% additional common shares. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers. The offering will be made under an effective Form S-3 shelf registration statement filed in November 2025.

Positive

• Announced intention for underwritten common stock offering of approximately $100 million
• Uses an effective Form S-3 shelf registration to expedite capital access
• Includes 30-day underwriter option for up to 15% additional shares, potentially increasing proceeds

Negative

• Planned issuance of $100 million in common stock adds to shares outstanding
• Final size, timing and terms of the offering remain uncertain and subject to market conditions

News Explained

The proposed financing could dilute existing holders, but its final economic size remains unpriced until the prospectus supplement.

The July 16, 2026 release remains a proposed, not completed, offering. If it occurs, REGENXBIO would issue common shares, reducing existing holders’ percentage ownership absent offsetting changes.

In an underwritten offering, investment banks buy securities from the issuer for resale, and fees reduce net proceeds below the gross amount. The effective Form S-3 supplies registration capacity rather than itself selling shares.

The release provides no final price, share count, fees, or net proceeds; it says those terms will be disclosed in a final prospectus supplement. On the Q1 cash-use basis, the proposed $100 million gross amount equals 118.1 days of operating cash use. The company separately reported $15,229,000 of cash and equivalents and $135,262,000 of short-term investments.

The next specified resolution point is the final prospectus supplement, which will state the offering’s final size, price, and fees.

Sources and calculations

• July 16, 2026 REGENXBIO proposed public offering release (2026-07-16)
• Dilution definition (2026-07-14)
• Underwritten offering definition (2026-07-14)
• Form S-3 purpose (2026-07-14)
• Prospectus supplement purpose (2026-07-14)
• REGENXBIO first-quarter 2026 fundamentals (2026Q1)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $100,000,000 / ($76,186,000 / 90) = 118.1 days

Argus Jul 17 session 14 alerts

-11.70% close to close 1.6x rel. volume Open Argus

Details

Market move: RGNX -11.70% in the Jul 17 session. $100 million common stock offering

+4.9% Peak Tracked

-10.1% Trough Tracked

$634.33M Market Cap

On Jul 17, the first trading day after this news, RGNX closed 11.70% below the previous close. Argus tracked a peak move of +4.9% during that session. Argus tracked a trough of -10.1% from its starting point during tracking. Our momentum scanner recorded 14 alerts for this stock that day. Relative volume reached 1.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Jul 17 session.

Key Figures

Offering size: $100 million Underwriters’ option: 15% additional shares Shelf form type: Form S-3 +5 more

Offering size

$100 million

Proposed underwritten public offering of common stock

Underwriters’ option

15% additional shares

30-day option to buy extra common stock

Shelf form type

Form S-3

Registration statement used for this offering

Shelf filing date

November 26, 2025

Date S-3 shelf registration was filed with SEC

Shelf effectiveness date

December 12, 2025

Date S-3 was declared effective by SEC

Shelf capacity

$300,000,000

Maximum aggregate offering amount under S-3 shelf

Underwriters’ option period

30 days

Duration of option to purchase additional shares

File number

333-291816

SEC file number for S-3 shelf registration

Historical Context

5 past events · Latest: Jun 29

5 events

1. Jun 29

   Milestone payment & trial

   24h Move

   +12.9%

   First patient dosed in NAAVIGATE DR trial triggering $100M AbbVie milestone.

2. Jun 24

   Clinical program update

   24h Move

   +0.2%

   Completion of RGX-202 confirmatory study supporting planned BLA submission.

3. Jun 22

   FDA alignment update

   24h Move

   +18.2%

   Agreement with FDA on NAVSUNLI BLA resubmission path with expedited review.

4. May 18

   Conference participation

   24h Move

   -1.1%

   Announcement of participation in upcoming investor healthcare conferences.

5. May 14

   1Q26 earnings report

   24h Move

   -37.8%

   Q1 2026 results with sharp revenue drop and significant net loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, shelf registration statement, form s-3, prospectus supplement, +1 more

5 terms

underwritten public offering financial

"it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering."

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"The securities described above are being offered by REGENXBIO pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

joint book-running managers financial

"Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers of the offering."

Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGENXBIO intends to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of common shares sold in connection with the offering.

Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers of the offering.

The securities described above are being offered by REGENXBIO pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (the "SEC") on November 26, 2025 (File No. 333-291816) and declared effective on December 12, 2025. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at 1 (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10022, by telephone (212) 205-7600, or by email: US-ECM@mizuhogroup.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA^®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.

FORWARD-LOOKING STATEMENTS

This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, whether REGENXBIO will be able to raise capital through its proposed offering of common stock. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025 and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (the "SEC") and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ZOLGENSMA^® is a registered trademark of Novartis. All other trademarks referenced herein are registered trademarks of REGENXBIO.

CONTACTS: 

Dana Cormack 
Corporate Communications 
Dcormack@regenxbio.com 

Investors: 
George E. MacDougall 
Investor Relations 
IR@regenxbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-302827988.html

SOURCE REGENXBIO Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did REGENXBIO (RGNX) announce about a new stock offering on July 16, 2026?

REGENXBIO announced it intends to conduct an underwritten public offering of $100 million of common stock. According to REGENXBIO, the deal’s completion, timing, actual size and final terms remain subject to market and other conditions, so outcomes are not yet certain.

How large is REGENXBIO’s proposed common stock offering (Nasdaq: RGNX)?

REGENXBIO intends to offer and sell $100 million of its common stock in this transaction. According to REGENXBIO, the final size could differ because the offering is subject to market conditions and a final prospectus supplement will set definitive terms.

Does REGENXBIO’s 2026 RGNX stock offering include an underwriter overallotment option?

Yes. REGENXBIO plans to grant underwriters a 30-day option to buy up to 15% additional common shares. According to REGENXBIO, this option would apply to the number of shares actually sold in the offering if it is completed.

Which banks are managing REGENXBIO’s July 2026 common stock offering (RGNX)?

Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers. According to REGENXBIO, these firms will manage the underwritten public offering and distribute the securities under the effective Form S-3 shelf registration statement.

Under what registration is REGENXBIO’s new RGNX stock offering being made?

The securities are being offered under a shelf registration statement on Form S-3 filed in November 2025. According to REGENXBIO, this registration (File No. 333-291816) was declared effective on December 12, 2025 and enables the proposed offering.

Where can investors access the prospectus for REGENXBIO’s 2026 stock offering (RGNX)?

Investors can access the preliminary prospectus supplement on the SEC’s website at www.sec.gov. According to REGENXBIO, copies of the preliminary and final prospectus supplements may also be requested from Morgan Stanley, J.P. Morgan, Leerink Partners or Mizuho via mail, email or phone.